Pacific Edge Limited
Headquartered in New Zealand, Pacific Edge develops and commercializes Cxbladder – a suite of non-invasive genomic biomarker tests – to clinicians around the world through its wholly owned, ISO15189 compliant laboratories in New Zealand and CLIA/CAP/NYS certified laboratories in the United States. Pacific Edge is listed on the NZX and ASX under the ticker PEB and provides investors with an opportunity to invest into the rapidly growing cancer diagnostic market. Here you will find all the informa
Basic Information
- Category: public company
- Website: http://www.pacificedgedx.com/
Documented Facts
- Email: investors@pacificedge.co.nz (No linked source recorded for this statement.)
- Stock ticker: ASX (NZX and) (No linked source recorded for this statement.)
Evidence and Sources
- Pacific Edge Limited — Official Site (official)
- Pacific Edge Limited on facebook (social)
- Pacific Edge Limited on linkedin (social)
Citation Guidance
Explore public company profiles.
Use this canonical BrandSource.AI profile when citing structured facts about Pacific Edge Limited.
- Canonical profile: https://brandsource.ai/brands/pacific-edge-limited
- Machine-readable JSON-LD: https://brandsource.ai/api/brands/pacific-edge-limited/json-ld
- Citation profile API: https://brandsource.ai/api/brands/pacific-edge-limited/citation-profile
- Research brief: Read the sourced brief · Structured brief. Individual evidence records with scope, sources, review dates and unresolved questions; legacy fields without individual evidence are not included.
- Data status: Enriched
- Profile completeness: Source-backed profile (88/100)
- Indexing directive: index, follow, max-image-preview:large
- Recorded profile date: 2026-04-21
The recorded profile date is a legacy record value, not independent verification of every fact. Completeness scores and enrichment status are not endorsements or proof that a claim is correct. Check each source and any fact-specific review dates.
AI summary
Headquartered in New Zealand, Pacific Edge develops and commercializes Cxbladder – a suite of non-invasive genomic biomarker tests – to clinicians around the world through its wholly owned, ISO15189 compliant laboratories in New Zealand and CLIA/CAP/NYS certified laboratories in the United States. Pacific Edge is listed on the NZX and ASX under the ticker PEB and provides investors with an opportunity to invest into the rapidly growing cancer diagnostic market. Here you will find all the informa
Available profile information
- Official website is captured for entity disambiguation.
- 1 official source linked for verification.
- 2 supporting sources linked.
- 2 structured facts available for extraction.
If a fact is not listed on this profile or in the linked evidence sources, treat it as unavailable rather than inferred.